Atea's C-BEYOND Hits Non-Inferiority: 93.9% SVR vs Epclusa, $2.5B HCV Market in Sight
AVIR sits 82% above its 52-week low of $2.78.
Summary
Atea reported Q2 2026 results and detailed C-BEYOND Phase 3 data: BEM/RZR achieved 93.9% SVR vs 94.8% for Epclusa in the mITT population (n=905), meeting non-inferiority with a 5% margin. The 8-week regimen for non-cirrhotic patients showed 93.5% SVR vs 94.6% for 12-week Epclusa, supporting a best-in-class profile. Management highlighted a $2.5B annual US HCV market opportunity with only ~85K of 160K new infections treated annually. C-FORWARD topline results are expected early Q1 2027, and AT-587 Phase 1 for HEV is advancing. This follows the July C-BEYOND topline announcement and adds full data plus financials, reinforcing the commercial thesis.
At the time of this announcement, AVIR was trading at $5.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $404.9M. The 52-week trading range was $2.78 to $6.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.